LNSR Share Price Performance
US$6.06
-8.00 (-56.90%)
51.5% undervalued intrinsic discount
US$12.50
Fair Value
Price US$6.06
AnalystConsensusTarget US$12.50
AnalystHighTarget US$15.00
Fair ValueUS$12.50
Share Pricen/a
LENSAR, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
LNSR Community Narratives
AN
Fair Value US$12.5 51.5% undervalued intrinsic discount
Global System Placements Will Improve Operating Room Efficiency
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$15 59.6% undervalued intrinsic discount
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
59.6% undervalued intrinsic discount
Fair Value
Profit Margin
9.29%
Future PE
20.47x
Price in 2029
US$18.76
Global System Placements Will Improve Operating Room Efficiency
Key Takeaways Strong system placements and contract pipelines in international markets enhance potential for sustained revenue growth and competitive advantage. Strategic focus on ALLY System adoption in diverse settings and converting competitive users drives increased productivity, recurring revenues, and profitability.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$12.5
51.5% undervalued intrinsic discount
Fair Value
Profit Margin
5.84%
Future PE
23.9x
Price in 2029
US$15.12
Trending Discussion
Recently Updated Narratives
AN
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Fair Value: US$15 59.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LNSR: Buy Rating And Post Deal Reset Will Drive Future Reassessment
Fair Value: US$12.5 51.5% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
LENSAR, Inc. Key Details
About LNSR
- Founded
- 2004
- Employees
- 150
- CEO
- WebsiteView website
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
